Want to see CH:ALC full AI Analyst Report?
ALC Stock Chart & Stats
CHF63.90
-CHF2.00(-2.39%)
At close: 4:00 PM EST
CHF63.90
-CHF2.00(-2.39%)
Day’s Range― - ―
52-Week RangeCHF47.80 - CHF74.34
Previous CloseN/A
Volume235.38K
Average Volume (3M)1.48M
Market Cap
CHF28.33B
Enterprise ValueCHF31.95K
Total Cash (Recent Filing)CHF1.66B
Total Debt (Recent Filing)CHF5.25B
Price to Earnings (P/E)42.3
Beta1.05
Next Earnings
Aug 10, 2026EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)1.65
Shares Outstanding499,700,000
10 Day Avg. Volume1,500,019
30 Day Avg. Volume1,484,208
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF70.21Price Target Upside9.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)2.75
Revenue Forecast (FY)CHF8.80B
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageSustained low leverage and a sizable equity base provide financial flexibility for R&D, capital placements, and buybacks. This reduces refinancing risk and supports durable investment in product launches and installed-base expansions that drive recurring consumables revenue over multi-year cycles.
Equipment Momentum / Installed BaseAccelerating Unity equipment placements expand the installed base, creating a multi-year annuity of consumables and services. Durable equipment adoption deepens customer relationships, raises switching costs, and supports steady recurring revenue tied to procedure volumes rather than one-time sales.
Pharmaceutical Launch Traction (Tryptyr)Rapid share gains, high refill rates and expanding coverage signal sticky demand and pathway to steady revenue in ocular pharmaceuticals. Strong early commercial traction suggests durable adoption, improving lifecycle revenue visibility and diversifying growth beyond device and lens sales.
Bears Say
Free Cash Flow Softness (TTM Decline)A meaningful TTM free cash flow decline and sub-1x cash-to-earnings ratio weaken the firm's ability to self-fund launches, repurchases, or weather downturns. Persistent FCF softness reduces optionality and raises reliance on operational improvement to sustain capital returns over time.
Tariff-driven Margin PressureElevated import tariffs materially compress gross margins and introduce an ongoing structural headwind to profitability. If tariffs and trade frictions persist, they can blunt margin expansion from productivity gains and product mix, pressuring long-term operating margin sustainability.
China Weakness & Competitive IntensitySlower demand and tougher competition in China and other markets limit a key growth runway for premium IOLs and implantables. Sustained regional weakness or pricing pressure can cap global penetration rates and constrain long-term revenue and margin expansion from higher-value products.
Alcon News
ALC FAQ
What was Alcon’s price range in the past 12 months?
Alcon lowest stock price was CHF47.80 and its highest was CHF74.34 in the past 12 months.
What is Alcon’s market cap?
Alcon’s market cap is CHF28.33B.
When is Alcon’s upcoming earnings report date?
Alcon’s upcoming earnings report date is Aug 10, 2026 which is in 21 days.
How were Alcon’s earnings last quarter?
Alcon released its earnings results on May 05, 2026. The company reported CHF0.662 earnings per share for the quarter, beating the consensus estimate of CHF0.636 by CHF0.026.
Is Alcon overvalued?
According to Wall Street analysts Alcon’s price is currently Undervalued.
Does Alcon pay dividends?
Alcon pays a Annually dividend of CHF0.28 which represents an annual dividend yield of 0.49%. See more information on Alcon dividends here
What is Alcon’s EPS estimate?
Alcon’s EPS estimate is 0.6.
How many shares outstanding does Alcon have?
Alcon has 499,700,000 shares outstanding.
What happened to Alcon’s price movement after its last earnings report?
Alcon reported an EPS of CHF0.662 in its last earnings report, beating expectations of CHF0.636. Following the earnings report the stock price went down -10.958%.
Which hedge fund is a major shareholder of Alcon?
Currently, no hedge funds are holding shares in CH:ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF70.21 (9.87% Upside)
CHF70.21 (9.87% Upside)
Blogger Sentiment
Bullish
CH:ALC Sentiment 70%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.81%
12-Months-Change
Fundamentals
Return on Equity
0.49%
Trailing 12-Months
Asset Growth
1.97%
Trailing 12-Months
Company Description
Alcon
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
ALC Stock 12 Month Forecast
Average Price Target
CHF70.21
▲(9.87% Upside)